206 results
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of market acceptance of APHEXDA; the timing, progress and results of current and future preclinical studies and clinical trials and our research … and development programs; regulatory matters, concerns about our financial position, operations results, litigation, government regulation, developments
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
have been mainly focused on research and development. We have incurred losses since inception, principally as a result of research and development … impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline or continue our
6-K
EX-99
BLRX
Bioline Rx Ltd
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
.
Research and development expenses for the year ended December 31, 2023, were $12.5 million, compared to $17.6 million for the year ended December 31 … thousands
REVENUES
COST OF REVENUES
GROSS PROFIT
RESEARCH AND DEVELOPMENT EXPENSES
SALES AND MARKETING EXPENSES
GENERAL AND ADMINISTRATIVE EXPENSES
IMPAIRMENT
F-3
BLRX
Bioline Rx Ltd
29 Dec 23
Shelf registration (foreign)
4:15pm
, or the IIA (formerly known as the Office of the Chief Scientist), which has provided funding in relation to our research and development programs. Through
6-K
EX-99
vh85c6ux4e
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
tybejj5
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
euc9k57hyq
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
hjd5bx4xnew8bhlshbr
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
w17dz6zn2 n5l
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
thjcky
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
h0lxb
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
z21anoxm0e
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
1e51gdzib4o
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
u39bd hgpm
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
ll0v29ctwgt gg0vzl
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
ywzavk0uy cc
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
v0e57eaoc78vryvre8c
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
jq3snf1ytzss2s 3zq6s
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
424B5
u7486agw
20 Sep 22
Prospectus supplement for primary offering
4:30pm